valsartan has been researched along with n-(n-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Lei, S; Lyu, C; Shao, Y; Wang, Q; Wu, C; Yuan, Q | 1 |
2 other study(ies) available for valsartan and n-(n-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
[Valsartan inhibits angiotensin II-Notch signaling of mesangial cells induced by high glucose].
Topics: Angiotensin II; Animals; Blotting, Western; Cells, Cultured; Dipeptides; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Fibronectins; Glucose; Mesangial Cells; Rats; Receptor, Notch1; Signal Transduction; Time Factors; Transforming Growth Factor beta; Valsartan | 2016 |